Notification of the Stage III pathology accreditation measures in response to the COVID-19 Pandemic
Notification of the Stage III pathology accreditation measures in response to the COVID-19 pandemic
Accreditation Requirements for SARS-CoV-2 Testing
It is a requirement for laboratories performing SARS-CoV-2 testing to be specifically accredited for SARS-CoV-2 testing in order to be eligible for Medicare rebates.
Laboratories performing SARS-CoV-2 testing are expected to contact to NATA to confirm their accreditation status. All laboratories performing SARS-CoV-2 testing are expected to be accredited by
20 December 2020.
NPAAC Strategic Plan 2020–2025
The revised NPAAC Strategic Plan 2020–2025 and NPAAC Risk Matrix are available.
Guidelines for COVID-19 Temporary Collection Facilities (Drive through and Pop-up)
As part of the response to the COVID-19 pandemic, temporary collection facilities have been established by either state/ territory governments or laboratory providers for the collection of specimens from patients. This is with the aim of providing more access to collection services that will enable more testing for COVID to occur.
To support the temporary COVID collection facilities, guidance is provided with the aim of reducing any potential risks to patients and aimed at ensuing quality pathology results.
COVID Point of Care Testing
NPAAC provides advice and quality standards for pathology testing that is risk based with the aim of mitigating potential risks to patient safety.
To support the increase in testing demand for COVID-19, NPAAC has provided some guidance on key considerations that are applicable to PoCT used in healthcare settings.
Should you have any queries or wish to provide comments to inform document reviews, please email the NPAAC Secretariat..